Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The prevention and treatment of coronary heart disease is a major challenge in the overall management of the patient with type 2 diabetes. Diabetic dyslipidaemia is an important risk factor and is open to therapeutic intervention. However, as yet there are no primary or secondary coronary heart disease prevention trials of lipid-lowering therapy reported in diabetic populations. In this review, on-going clinical trials of lipid-lowering therapy in specific diabetic populations will be described.


Journal article


Curr Opin Lipidol

Publication Date





621 - 626


Anticholesteremic Agents, Arteriosclerosis, Atorvastatin Calcium, Clinical Trials as Topic, Coronary Disease, Diabetes Mellitus, Type 2, Fenofibrate, Heptanoic Acids, Humans, Hyperlipidemias, Hypolipidemic Agents, Pyrroles, Risk Factors